Correction: Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review

Correction to: Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review Horm Metab Res eFirst DOI: 10.1055/a-2787-1205 10.1055/a-2787-1205 This article was changed according to the erratum on February 16th 2026. In the above-mentioned article "Faculty of Pharmacy" was added to the 6th affiliation. This was corrected in the online version on 16.02.2026. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany